zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
July 30, 2024 08:38 ET | Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 09, 2024 09:00 ET | Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Expands Executive Leadership Team
June 25, 2024 07:30 ET | Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
June 03, 2024 11:00 ET | Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
BES_Mark.jpg
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
April 03, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zevra Therapeutics, Inc....
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
November 20, 2023 07:30 ET | Zevra Therapeutics
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET | Zevra Therapeutics
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results.
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
October 19, 2023 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
October 10, 2023 07:30 ET | Zevra Therapeutics
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
October 05, 2023 07:30 ET | Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...